摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Methylamino-2-methyl-3-pentanon | 2997-81-1

中文名称
——
中文别名
——
英文名称
2-Methylamino-2-methyl-3-pentanon
英文别名
2-Methyl-2-(methylamino)pentan-3-one
2-Methylamino-2-methyl-3-pentanon化学式
CAS
2997-81-1
化学式
C7H15NO
mdl
——
分子量
129.202
InChiKey
YNNZKYBSHFTPGU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    9
  • 可旋转键数:
    3
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.86
  • 拓扑面积:
    29.1
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS
    申请人:Ewing R. William
    公开号:US20080045461A1
    公开(公告)日:2008-02-21
    The subject matter described herein provides novel human glucagon-like peptide-1 (GLP-1) receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. The described compounds include chemically modified peptides that may stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The disclosed and claimed peptides show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.
    本文所述主题提供了新颖的人类胰高血糖素样肽-1(GLP-1)受体调节剂,其生物活性类似或优于天然GLP-1肽,因此可用于治疗或预防与GLP活性相关的疾病或疾病。所述化合物包括化学修饰的肽,可以刺激2型糖尿病患者的胰岛素分泌,但也产生其他有益的胰岛素促分泌反应。这些合成肽GLP-1受体调节剂表现出对蛋白酶解的稳定性增加,使它们成为口服或静脉注射的理想治疗候选药物。所披露和声称的肽显示出理想的药代动力学特性和糖尿病疗效模型的理想效力。
  • N-terminally modified GLP-1 receptor modulators
    申请人:Ewing R. William
    公开号:US20070021346A1
    公开(公告)日:2007-01-25
    The subject matter described herein provides novel human glucagon-like peptide-1 (GLP-1) receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. The described compounds include chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The disclosed and claimed peptides show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.
    本文所描述的主题提供了一种新颖的人类胰高血糖素样肽-1(GLP-1)受体调节剂,其生物活性类似或优于天然GLP-1肽,因此可用于治疗或预防与GLP活性相关的疾病或障碍。所描述的化合物包括化学修饰的肽,不仅能够刺激II型糖尿病患者的胰岛素分泌,还产生其他有益的胰岛素促进反应。这些合成肽GLP-1受体调节剂表现出对蛋白酶解的稳定性增加,使它们成为口服或静脉注射的理想治疗候选药物。所披露和要求的肽具有理想的药代动力学特性和糖尿病疗效模型中的理想效力。
  • NITROGEN-CONTAINING HETEROCYCLIC COMPOUND
    申请人:KYOWA HAKKO KIRIN CO., LTD.
    公开号:US20150299214A1
    公开(公告)日:2015-10-22
    The present invention provides a heterocyclic compound represented by the following formula (I), wherein X A represents CH and the like, R 1 represents cycloalkyl optionally having substituent(s) and the like, L represents a bond and the like, Y A represents —NH— and the like, R 2 represents a hydrogen atom and the like, R 3A represents the following formula (R 3A -1) (wherein, R 3 represents hydroxy and the like) and the like, and R 4A represents the following formula (R 4A -1) (wherein, R 4 and R 5 are the same or different and each represents a hydrogen atom and the like) and the like, or a pharmaceutically acceptable salt thereof, which is useful as a prophylactic and/or therapeutic agent for skin diseases and the like, and the like.
    本发明提供一种杂环化合物,其化学式表示为(I),其中XA代表CH等,R1代表环烷基,可选地具有取代基等,L代表键等,YA代表—NH—等,R2代表氢原子等,R3A代表下式(R3A-1)(其中,R3代表羟基等)等,R4A代表下式(R4A-1)(其中,R4和R5相同或不同,且每个代表氢原子等)等,或其药学上可接受的盐,其作为预防和/或治疗皮肤疾病等的药物具有用途。
  • US9701689B2
    申请人:——
    公开号:US9701689B2
    公开(公告)日:2017-07-11
查看更多